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Abstract
Hepatocellular carcinoma (HCC) is the third leading cause of cancer death
globally. China contributes to half of the global incidence of liver cancer, with
about 70-85% being HCC. Definitive treatment for this condition would be
surgical resection with liver transplant but for obvious reasons, the majority of
affected patients are unable to meet the necessary criteria. Sorafenib is a form of
chemotherapy that has been the mainstay treatment of HCC since its approval in
2007. More recently, the combination of Bevacizumab and Atezolizumab has
shown greater efficacy in the treatment of unresectable HCC. Additionally, this
new combination therapy shows favorable results in terms of long-term adverse
effects. However, on an economic standpoint, the cost of long-term therapy may
hinder its progression towards mainstay treatment.

Introduction
● Sorafenib is a multikinase inhibitor associated with tumor cell proliferation
and blood supply
● Bevacizumab is a selective VEGF inhibitor which demonstrates a more
potent inhibitory effect on tumor angiogenesis than Sorafenib
● Atezolizumab is a checkpoint inhibitor of PDL1, which plays a role in
T-cell suppression
● The combination of targeted therapy (Bevacizumab) and checkpoint
inhibition (Atezolizumab) has shown promising results through the
IMbrave150 trials

Results
● Cheng A-L, Qin S, Ikeda M, et al. Updated efficacy and safety data from
IMBRAVE150: Atezolizumab plus bevacizumab vs. Sorafenib for unresectable
hepatocellular carcinoma. Journal of Hepatology. 2021;76(4):862-873.
doi:10.1016/j.jhep.2021.11.030
○ RCT of 501 patients designed to test the efficacy of Bevacizumab with Atezolizumab
in the treatment of unresectable HCC when compared to Sorafenib (First-line)
● Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus Bevacizumab in Unresectable
Hepatocellular Carcinoma. N Engl J Med. 2020;382(20):1894-1905.
doi:10.1056/NEJMoa1915745
○ RCT of 336 patients designed to test the efficacy of Bevacizumab wth Atezolizumab
in the treatment of unresectable HCC when compared to Sorafenib (First-line)
● Li D, Toh H, Merle P, et al. O-8 Atezolizumab + bevacizumab vs sorafenib for
unresectable hepatocellular carcinoma: Results from older adults enrolled in
IMbrave150. Annals of Oncology. 2020;31:234. doi:10.1016/j.annonc.2020.04.061
○ RCT of 252 patients designed to test the efficacy of Bevacizumab with Atezolizumab
in the treatment of unresectable HCC when compared to Sorafenib (First-line)
● Qin S, Ren Z, Feng Y-H, et al. Atezolizumab plus bevacizumab versus sorafenib in
the Chinese subpopulation with unresectable hepatocellular carcinoma: Phase 3
randomized, open-label IMBRAVE150 Study. Liver Cancer. 2021;10(4):296-308.
doi:10.1159/000513486
○ RCT of 194 patients designed to test the efficacy of Bevacizumab wth Atezolizumab
in the treatment of unresectable HCC when compared to Sorafenib (First-line)
● Su D, Wu B, Shi L. Cost-effectiveness of Atezolizumab Plus Bevacizumab vs
Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma.
JAMA Netw Open. 2021;4(2):e210037. doi:10.1001/jamanetworkopen.2021.0037
○ Partitioned survival model of 501 patients designed to test the cost-effectiveness of
Bevacizumab wth Atezolizumab in the treatment of unresectable HCC when
compared to Sorafenib (First-line)

Sample
Size (n)

Baseline
Status

Control

Outcome
Measures

Cheng et al
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Finn et al.

336
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treatment-naive,
U-HCC

Sorafenib

OSR, SP, SPRO

Li et al.

252

Systemic
treatment-naive,
U-HCC

Sorafenib

OSR, SP, SPRO

Qin et al.

194

Systemic
treatment-naive,
U-HCC

Sorafenib

ORR, OSR, SP,
SPRO

Su et al.

501

Systemic
treatment-naive,
U-HCC

N/A

QALY, ICUR,
NHB, NMB

Methods
● A literature search was conducted via Pubmed and EBSCO on January, 2022.
○ “adults AND hepatocellular carcinoma AND bevacizumab”
● A total of six articles were chosen based on the following criteria
○ Publication within the past 5 years
○ Appropriate adjuvant therapy (Atezolizumab)
○ Randomized-Controlled Trial with intent-to-treat population
○ Access to the full-text article

Discussion

U-HCC: Unresectable hepatocellular carcinoma, ORR: Objective Response Rate, OSR: Overall Survival Rate,
SP: Safety Profile, SPRO: Secondary Reported Patient Outcome, QALY: Quality Adjusted Life Years, ICUR:
Incremental Cost-Utility Ratio, NHB: Net Health Benefits, NMB: Net Monetary Benefits

● Findings
○ 4/4 Studies concluded that Atezolizumab plus Bevacizumab
therapy has greater efficacy than Sorafenib in the treatment
of patients with unresectable HCC
○ The partitioned survival model concluded that Atezolizumab
plus Bevacizumab therapy is not a cost-effective option
when compared with Sorafenib in the treatment of patients
with unresectable HCC
● Strengths
○ Blinded, independent review of imaging to prevent bias
○ Longevity of trials (12-28 months)
● Limitations
○ Open-label study design, lack of placebo infusions
○ Consistent patient population (Severity of HCC,
comorbidities)
● Future Implications
○ Further cost-effective analysis
○ 5-Year survival rate follow-up

Conclusion
● The research concluded that Atezolizumab and Bevacizumab
demonstrated greater efficacy in terms of overall survival rate,
safety profile, and secondary patient-reported outcomes
● However, the cost-effective analysis of both treatment arms
demonstrated that Atezolizumab and Bevacizumab is not a
economically sustainable option when compared with Sorafenib
● Potential future research include 3-5 year follow-up status post
treatment and further cost-effective analysis as prices may be
subjected to change
● Overall, if costs favor Bevacizumab and Atezolizumab in the
future, it may serve as the new mainstay treatment for HCC.

